Ratings Bangkok Dusit Medical Services OTC Markets

Equities

Market Closed - OTC Markets Other stock markets 14:54:23 28/12/2023 GMT			5-day change	1st Jan Change
0.8142 ^USD	+3.40%		-.--%	-.--%

05-14	Bangkok Dusit Medical Services Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Bangkok Dusit Medical Services Public Company Limited Announces Appointment of Kongkiat Kespechara as Executive Committee Member	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

The firm trades with high earnings multiples: 26.79 times its 2024 earnings per share.
With an enterprise value anticipated at 3.9 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

	1st Jan change	Capi.	ESG Refinitiv
BANGKOK DUSIT MEDICAL SERVICES	-.--%	11.65B	-
AIER EYE HOSPITAL GROUP CO., LTD.	-23.39%	15.56B	B+
IHH HEALTHCARE	+2.65%	11.58B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.37%	10.06B	B+
ENCOMPASS HEALTH CORPORATION	+29.48%	8.7B	B
RAMSAY HEALTH CARE LIMITED	-10.45%	7.16B	A-
THE ENSIGN GROUP, INC.	+8.05%	6.85B	B-
MOUWASAT MEDICAL SERVICES COMPANY	+3.94%	5.71B	D
FORTIS HEALTHCARE LIMITED	+13.33%	4.3B	B+
DALLAH HEALTHCARE COMPANY	-3.49%	4.3B	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality